Quantcast

Latest Human papillomavirus Stories

2014-08-05 08:34:12

HPV mRNA positive and Ct/Ng negative controls reduce repeat molecular testing MILFORD, Mass., Aug. 5, 2014 /PRNewswire/ -- SeraCare Life Sciences, a provider of high-quality biological materials that help optimize diagnostic performance, reliability and repeatability across the IVD lifecycle, today announced the launch of two new ACCURUN(®) products - the first HPV mRNA positive and Ct/Ng negative controls for the company. http://photos.prnewswire.com/prnvar/20140804/132910...

2014-08-04 09:40:28

University of California - San Diego Biomarker for head and neck cancers identified Although mutations in a gene dubbed "the guardian of the genome" are widely recognized as being associated with more aggressive forms of cancer, researchers at the University of California, San Diego School of Medicine have found evidence suggesting that the deleterious health effects of the mutated gene may in large part be due to other genetic abnormalities, at least in squamous cell head and neck...

2014-08-01 12:26:13

CHICAGO, Aug. 1. 2014 /PRNewswire-USNewswire/ -- As one of the 10 largest medical exhibitions in the U.S., the 2014 AACC Annual Meeting & Clinical Lab Expo is the place where breakthrough innovations in clinical testing and patient care are introduced to the healthcare world. This year, many of the trailblazing products displayed by the Expo's 650 exhibitors will include the latest diagnostic technology in the field of mobile health....

2014-08-01 10:49:36

Landes Bioscience A long-term follow-up study (HPV-023; NCT00518336) shows the sustained efficacy, immunogenicity and safety of GlaxoSmithKline's human papilloma virus (HPV) vaccine Cervarix. Women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine were followed for more than nine years, and vaccine efficacy (VE) against incident infection was 100%. This is the longest follow-up report for a licensed HPV vaccine. Visit https://www.landesbioscience.com/journals/vaccines/article/29532/...

2014-08-01 10:35:50

Johns Hopkins Medicine Physicians at Johns Hopkins have developed blood and saliva tests that help accurately predict recurrences of HPV-linked oral cancers in a substantial number of patients. The tests screen for DNA fragments of the human papillomavirus (HPV) shed from cancer cells lingering in the mouth or other parts of the body. A description of the development is published in the July 31 issue of JAMA Otolaryngology – Head & Neck Surgery. "There is a window of opportunity...

2014-07-29 16:26:30

VENLO, the Netherlands, July 29, 2014 /PRNewswire/ -- - Achieved Q2 2014 targets: Adjusted net sales of $331.2 million (+4% CER); adjusted operating income of $81.2 million and 25% operating margin; adjusted EPS of $0.26 CER - H1 2014 adjusted net sales rise approximately 8% CER excluding U.S. HPV tests, in line with full-year 2014 goal; H1 2014 free cash flow rises 28% to $77 million...

2014-07-28 10:35:17

Brigham and Women's Hospital Researchers demonstrate novel approach in cervical cancer prevention A study published online in the International Journal of Cancer earlier this month describes a novel approach to preventing cervical cancer based on findings showing successful reduction in the risk of cervical cancer after removal of a discrete population of cells in the cervix. The findings come from a study that looked at squamocolumnar junction cells, or SCJ cells. These cells...

2014-07-25 23:08:11

A recent study on PositiveSingles.com has shown that the number of people living with HSV and HPV has increased dramatically when compared to those who are living with other STDs such as HIV, hepatitis, and more. Los Angeles California (PRWEB) July 25, 2014 Recently, the largest herpes dating website PositiveSingles.com analyzed STD status of all its members and found that there had been a large increase in the number of members living with the HSV and/or HPV virus. Living with a sexually...

2014-07-23 08:32:38

Treatment with VGX-3100 induces regression of precancerous cervical disease and clears HPV infection with robust T cell responses PLYMOUTH MEETING, Pa., July 23, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced successful results from its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia 2/3 (CIN2/3) associated with human papillomavirus (HPV) types 16 or 18. Treatment...

2014-06-23 04:20:45

Inovio's Immunotherapy will Treat Women with Inoperable HPV-caused Cancer BLUE BELL, Pa., June 23, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity, clinical responses and disease-free survival of its DNA immunotherapy product, INO-3112, in treating human papillomavirus (HPV)-associated cervical cancer. INO-3112 is a combination of Inovio's lead active immunotherapy...


Latest Human papillomavirus Reference Libraries

0_d7e189bb6feb0f5663af7d072b6f51c6
2011-02-17 14:56:32

A human papillomavirus (HPV), a member of the papillomavirus family, is capable of infecting humans. HPVs establish productive infections in the skin or mucous membranes. Most of the 200 known types cause no symptoms in most people. Some types can cause warts, while others can lead to cancer. There are more than 30 to 40 types of HPV that are typically transmitted through sexual contact and infect the anogenital region. High risk HPV, can lead to cancer, in fact HPV infection is a cause of...

More Articles (1 articles) »
Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related